A prospective, randomized clinical trial of universal WBC reduction

Transfusion

Volumn 42, Issue 9, 2002, Pages 1114-1122

  Dzik, W H ^a,b,c,d,e   Anderson, J K ^a,b,c,d,e   O'Neill, E M ^a,b,c,d,e   Assmann, S F ^a,b,c,d,e   Kalish, L A ^a,b,c,d,e   Stowell, C P ^a,b,c,d,e  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b BAXTER HEALTHCARE CORPORATION   (United States)

^c Unimed Pharmaceuticals Inc   (United States)

^d AMERICAN RED CROSS BLOOD SERVICES   (United States)

^e NEW ENGLAND RESEARCH INSTITUTES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT;

ADOLESCENT; ADULT; AGED; ARTICLE; BACTERIAL INFECTION; BLOOD COMPONENT THERAPY; BLOOD TRANSFUSION; CHILD; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST BENEFIT ANALYSIS; DRUG UTILIZATION; ECONOMICS; FEMALE; FEVER; HOSPITAL ADMISSION; HOSPITAL COST; HUMAN; INCIDENCE; INFANT; LENGTH OF STAY; LEUKOCYTE; MALE; METHODOLOGY; MIDDLE AGED; MORTALITY; OUTCOME ASSESSMENT; PRESCHOOL CHILD; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RISK MANAGEMENT; STANDARD; STATISTICS; UNITED STATES;

ADOLESCENT; ADULT; AGED; ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; BLOOD COMPONENT TRANSFUSION; BLOOD TRANSFUSION; BOSTON; CHILD; CHILD, PRESCHOOL; COST-BENEFIT ANALYSIS; DRUG UTILIZATION; FEMALE; FEVER; HOSPITAL COSTS; HOSPITAL MORTALITY; HUMANS; INCIDENCE; INFANT; LENGTH OF STAY; LEUKOCYTES; MALE; MIDDLE AGED; OUTCOME ASSESSMENT (HEALTH CARE); PATIENT ADMISSION; PROSPECTIVE STUDIES; RISK MANAGEMENT;

EID: 0036730626     PISSN: 00411132     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1537-2995.2002.00182.x     Document Type: Article

References (28)

1. 1 Heddle NM, Klama L, Meyer R, et al. A randomized controlled trial comparing plasma removal with white cell reduction to prevent reactions to platelets. Transfusion 1999 ; 39: 231 ‐ 8.
2. 2 Leukocyte reduction and ultraviolet B, irradiation of platelets to prevent alloimmunization and refractoriness to platelet transfusions. The Trial to Reduce Alloimmunization to Platelets Study Group. N Engl J Med 1997;337:1861‐9.
3. 3 Bowden RA, Slichter SJ, Sayers M, et al. A comparison of filtered leukocyte‐reduced and cytomegalovirus (CMV) seronegative blood products for the prevention of transfusion‐associated CMV infection after marrow transplant. Blood 1995 ; 86: 3598 ‐ 603.
4. 4 Vamvakas EC, Blajchman MA, editors. Immunomodulatory effects of blood transfusion. Bethesda: American Association of Blood Banks; 1999.
5. 5 Jensen LS, Andersen AJ, Christiansen PM, et al. Postoperative infection and natural killer cell function following blood transfusion in patients undergoing elective colorectal surgery. Br J Surg 1992 ; 79: 513 ‐ 6.
6. 6 Heiss MM, Mempel W, Jauch KW, et al. Beneficial effect of autologous blood transfusion on infectious com‐ plications after colorectal cancer surgery. Lancet 1993 ; 342: 1328 ‐ 33, erratum in Lancet 1994;343:64.
7. 7 Jensen LS, Kissmeyer‐Nielsen P, Wolff B, et al. Randomised comparison of leucocyte‐depleted versus buffy‐coat‐poor blood transfusion and complications after colorectal surgery. Lancet 1996 ; 348: 841 ‐ 5.
8. 8 Van De Watering LM, Hermans J, Houbiers JG, et al. Beneficial effects of leukocyte depletion of transfused blood on postoperative complications in patients undergoing cardiac surgery: a randomized clinical trial. Circulation 1998 ; 97: 562 ‐ 8.
9. 9 Busch OR, Hop WC, Hoynck van Papendrecht MA, et al. Blood transfusions and prognosis in colorectal cancer. N Engl J Med 1993 ; 328: 1372 ‐ 6.
10. 10 Houbiers JG, Brand A, Van De Watering LM, et al. Randomized controlled trial comparing transfusion of leucocyte‐depleted or buffy‐coat‐depleted blood in surgery for colorectal cancer. Lancet 1994 ; 344: 573 ‐ 8.
11. 11 Tartter PI, Mohandas K, Azar P, et al. Randomized trial comparing packed red cell blood transfusion with and without leukocyte depletion for gastrointestinal surgery. Am J Surg 1998 ; 176: 462 ‐ 6.
12. 12 Titlestad IL, Ebbesen LS, Ainsworth AP, et al. Leukocyte‐depletion of blood components does not significantly reduce the risk of infectious complications: results of a double‐blinded, randomized study. Int J Colorectal Dis 2001 ; 16: 147 ‐ 53.
13. 13 Van De Watering L, Bilgin Y, Versteegh M, et al. Effects of leukocyte‐depletion of blood transfusions in cardiac surgery: a prospective randomized trial (abstract). Transfus Clin Biol 2001 ; 8 (Suppl. 1): 35a.
14. 14 Newsome JL, Ortolano GA, Janey M, et al. Impact of leukoreduced red blood cells (LR RBC) on length of stay (LOS) in surgical patients cost‐justifies universal leukocyte reduction (abstract). Transfusion 1999 ; 39: S551.
15. 15 Baron JF, Gourdin M, Bertrand M, et al. The effect of universal leukodepletion of packed red blood cells on postoperative infections in high‐risk patients undergoing abdominal aortic surgery. Anesth Analg 2002 ; 94: 529 ‐ 37.
16. 16 Thurer RL, Luban NL, AuBuchon JP, et al. Universal WBC reduction. Transfusion 2000 ; 40: 751 ‐ 2.
17. 17 College of American Pathologists policy on universal leukoreduction. Available from: URL: http://cap.org/html/lip/transmed/Leukoreduction.doc
18. 18 Lutz P, Dzik WH. Large‐volume hemocytometer chamber for accurate counting of white cells (WBCs) in WBC‐ reduced platelets: validation and application for quality control of WBC‐reduced platelets prepared by apheresis and filtration. Transfusion 1993 ; 33: 409 ‐ 12.
19. 19 Dumont LJ, Dzik WH, Rebulla P, Brandwein H. Practical guidelines for process validation and process control of white cell‐reduced blood components: report of the Biomedical Excellence for Safer Transfusion (BEST) Working Party of the International Society of Blood Transfusion (ISBT). Transfusion 1996 ; 36: 11 ‐ 20.
20. 20 Dzik S, AuBuchon J, Jeffries L, et al. Leukocyte reduction of blood components: public policy and new technology. Transfus Med Rev 2000 ; 14: 34 ‐ 52.
21. 21 Nightingale S. Advisory Committee on Blood Safety & Availability. Bloodsafety Summary—January 2001. Washington, DC: U.S. Department of Health and Human Services; 2001. Available from: URL: http://www.hhs.gov/bloodsafety/summaries/sumjan01.html
22. 22 Ratko TA. Technology assessment: leukocyte‐reduced cellular blood components. Oak Brook, IL: University HealthSystem Consortium; 2001.
23. 23 Vamvakas EC, Blajchman MA. Universal WBC reduction: the case for and against. Transfusion 2001 ; 41: 691 ‐ 712.
24. 24 Busch MP, Lee TH, Heitman J. Allogeneic leukocytes but not therapeutic blood elements induce reactivation and dissemination of latent human immunodeficiency virus type I infection: implications for transfusion support of infected patients. Blood 1992 ; 80: 2128 ‐ 35.
25. 25 Collier AC, Kalish LA, Busch MP, et al. Leukocyte‐reduced red blood cell transfusions in patients with anemia and human immunodeficiency virus infection. The Viral Activation Transfusion Study: a randomized controlled trial. JAMA 2001 ; 285: 1592 ‐ 601.
26. 26 Heiss MM, Mempel W, Jauch KW, et al. Blood transfusion‐modulated tumor recurrence: first results of a randomized study of autologous versus allogeneic blood transfusion in colorectal cancer surgery. J Clin Oncol 1994 ; 12: 1859 ‐ 67.
27. 27 Van De Watering LM, Brand A, Houbiers JG, et al. Perioperative blood transfusions, with or without allogeneic leucocytes, relate to survival, not to cancer recurrence. Br J Surg 2001 ; 88: 267 ‐ 72.
28. 28 Ghio M, Contini P, Mazzei C, et al. Soluble HLA Class I, HLA Class II, and Fas ligand in blood components: a possible key to explain the immunomodulatory effects of allogeneic blood transfusion. Blood 1999 ; 93: 1770 ‐ 7.